London, England — September 10, 2025 — Leads & Copy — Purespring Therapeutics will participate in the 2025 Bank of America Healthcare Trailblazers Private Company Conference on Wednesday, September 17, 2025, in Boston, USA.
The conference will feature one-on-one meetings.
Contact:
Peter Mulcahy, contact@purespringtx.com, +44 (0)20 3855 6324
Amber Fennell, Sarah Elton-Farr, purespring@icrhealthcare.com
Purespring is developing therapies to halt or prevent kidney disease by targeting the podocyte. Purespring’s platform approach enables streamlined gene therapy development for both acquired and genetic renal diseases.
The Company currently has a pipeline of programmes in development including the lead asset for treatment of IgA Nephropathy (IgAN) and other complement mediated kidney disease. The Company also has programmes for disease caused by mutations in the gene NPHS2, as well as other monogenic glomerular kidney diseases.
Purespring is backed by leading biotech investors, including Syncona Limited, Sofinnova Partners, Gilde Healthcare, Forbion, and the British Business Bank and has raised £115m ($149m) to date.
Peter Mulcahy, contact@purespringtx.com, +44 (0)20 3855 6324
Source: Purespring Therapeutics
